Paramyxoviruses as Vaccine Vectors Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

副粘病毒作为针对严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 的疫苗载体

• 批准号: 10272294
• 负责人: Ursula Buchholz
• 金额: $ 78.76万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10272294
• 关键词: 2019-nCoV; African Green Monkey; Antibodies; Attenuated; Attenuated Vaccines; CD4 Positive T Lymphocytes; CD8B1 gene; COVID-19; Cattle; Development; Disease; Disease Outbreaks; Dose; Human; Immunity; Immunization; Infection; Intranasal Administration; Modeling; Mucous Membrane; Natural Immunity; Para-Influenza Virus Type 3; Paramyxovirus; Population; Proteins; Respiratory System; SARS coronavirus; Serum; Severe Acute Respiratory Syndrome; Site; Structure of respiratory epithelium; Vaccines; Viral Vaccines; Viral Vector; Virus; base; conjunctiva; design; immunogenic; immunogenicity; neutralizing antibody; nonhuman primate; novel; pandemic disease; pathogen; response; vaccine candidate; vector; vector vaccine

There are no vaccines to protect against SARS-CoV-2 infection and COVID-19 disease caused by SARS-CoV-2. Effective vaccines are urgently needed. Paramyxovirus vectors expressing an immunogenic version of the SARS-CoV-2 S protein would provide novel live vaccines for intranasal administration, designed to be highly attenuated in humans while maintaining a high level of immunogenicity at the primary sites of infection of SARS-CoV-2. A major emphasis is being put on developing paramyxovirus vector vaccines that should not be restricted by pre-existing immunity in the human population. These viral vectors are designed to replicate in the superficial layers of the respiratory epithelium, inducing local mucosal and systemic innate immunity, virus-neutralizing serum antibodies, and CD8+ and CD4+ T cells. Intranasal paramyxovirus vector vaccines would provide systemic and local protection in the respiratory tract, the primary site of SARS-CoV-2 infection, and, similar to other live viral vaccines, are expected to rapidly induce immunity following a single dose of vaccine. Large quantities of vaccine doses could be generated rapidly.

没有疫苗可以预防SARS-CoV-2感染和由SARS-CoV-2引起的COVID-19疾病。迫切需要有效的疫苗。表达SARS-CoV-2 S蛋白的免疫原性版本的副粘病毒载体将提供用于鼻内施用的新型活疫苗，其被设计为在人类中高度减毒，同时在SARS-CoV-2的主要感染部位保持高水平的免疫原性。一个主要的重点是开发副粘病毒载体疫苗，不应受到预先存在的免疫力在人群中的限制。这些病毒载体被设计为在呼吸道上皮的浅表层中复制，诱导局部粘膜和全身先天免疫、病毒中和血清抗体以及CD 8+和CD 4 + T细胞。鼻内副粘病毒载体疫苗将在呼吸道（SARS-CoV-2感染的主要部位）中提供全身和局部保护，并且与其他活病毒疫苗类似，预期在单剂量疫苗后快速诱导免疫。可以迅速生产大量的疫苗剂量。